Lactulose Aiwa Pflaumenaroma T&d Pharma (Lactulose)

After oral administration, lactulose reaches the colon where bacterial enzymes split it into lactic and acetic acids. These short‑chain acids lower the colonic pH and create an osmotic gradient that draws water into the intestinal lumen, softening stool and stimulating peristalsis. In hepatic encephalopathy, the acidic environment converts ammonia to ammonium, reducing its absorption into the bloodstream.

The specific dose of lactulose is determined by the prescribing healthcare professional based on the individual’s condition, severity, and response to therapy. Typical starting regimens may vary, and the prescriber will adjust the amount to achieve the desired clinical effect while monitoring for tolerance and side effects.

Safety data for lactulose in pregnancy and lactation are limited. It is generally classified as a category C medication, meaning potential benefits may outweigh theoretical risks. Healthcare providers should evaluate the maternal condition and consider alternative therapies when appropriate, and advise breastfeeding mothers to monitor the infant for any adverse effects.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Lactulose is an osmotic laxative, differing from stimulant laxatives such as senna, which increase intestinal motility, and from polymeric agents like polyethylene glycol, which also retain water but are not metabolized by colonic bacteria. Lactulose uniquely lowers ammonia levels, making it the preferred choice for patients with hepatic encephalopathy, whereas other laxatives lack this hepatic benefit.

The oral solution should be stored at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging until use to maintain product stability.

Lactulose Aiwa Pflaumenaroma is taken orally as a liquid solution. The prescribed dose is measured with a calibrated dosing device or syringe, and it can be swallowed directly or mixed with a small amount of water, juice, or milk to improve palatability. Doses are usually spaced throughout the day as directed by the prescriber.

The most serious risks include severe dehydration and significant electrolyte disturbances such as hypokalemia or hyponatremia, which can arise from excessive fluid loss. Rarely, patients may experience allergic reactions manifesting as rash, urticaria, or angioedema. Prompt medical attention is required if any of these serious symptoms develop.

Lactulose should be avoided in individuals with known galactosemia, as they cannot metabolize the sugar component. It is also contraindicated in patients with intestinal obstruction, severe bowel perforation, or hypersensitivity to lactulose or any excipients in the formulation. Clinicians must assess each patient’s medical history before initiating therapy.